Indivior down 20% following adverse verdict to blockbuster Suboxone

Reckitt Benckiser’s spin-off Indivior lost over 20% as trading started today as a US federal court ruled that the generic version of blockbuster Suboxone, by US-based Alvogen, did not infringe a patent of Indivior’s.  The group’s CEO Shaun Thaxter immediately announced that the company’s legal team will appeal the court’s decision and will keep defending Suboxone from generics. Importantly, Indivior has two additional patents protecting Suboxone and not considered by the judges yet.

(Source: FT)